NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lantheus-holding ...

NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options Investors and analysts reacted promptly to Lantheus' revelations. The price of Lantheus' common stock declined dramatically. From a closing market price of $72.83 per share on August 5, 2025, Lantheus' stock price fell to $51.87 per share on August 6, 2025, a decline of about 28.8% ...

SAN DIEGO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”), have until November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lantheus as well as certa ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-form-2/?id=167840&from=3  CLASS PER ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming November 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR LANTHEUS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING. ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2025. SO WHAT: If you purchased Lantheus securities duri ...

NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or the "Company")Â (NASDAQ: LNTH). ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)?Did you purchase your shares between February 26, 2025 and August 5, 2025, inclusive?D ...

公司业务与产品 - Lantheus公司专注于开发、制造和商业化诊断和治疗产品 帮助全球临床医生诊断和治疗心脏病、癌症及其他疾病 [3] - 公司核心放射性药物肿瘤产品为Pylarify 这是一种用于辅助诊断和治疗前列腺癌的PET显像剂 [3] 财务表现与业绩指引 - 2025年第一季度Pylarify销售额出现同比下降 原因被归咎于"暂时性竞争干扰" [5] - 公司因此下调全年业绩指引 将年度增长预期从"低个位数到中个位数增长"调整为"持平至低个位数增长" [5] - 2025年8月6日公告显示Pylarify销售额同比下降8.3% 公司进一步大幅削减2025财年增长预期 [6] 股价表现与市场反应 - 2025年5月7日第一季度业绩公布后 公司股价单日跌幅超过23% [5] - 2025年8月6日第二次下调增长预期后 公司股价再次出现近29%的大幅下跌 [6] 法律诉讼情况 - 集体诉讼指控期间为2025年2月26日至8月5日 原告申请截止日期为2025年11月10日 [1] - 诉讼指控公司高管违反1934年证券交易法 称其营造了关于收入前景和增长预期的虚假印象 [4] - 指控称公司未能准确理解Pylarify市场的定价和竞争动态 其关于销售增长潜力和价格正常化的乐观报告与实际情况存在差距 [4]